vs
Side-by-side financial comparison of PROTHENA CORP PUBLIC LTD CO (PRTA) and Xenon Pharmaceuticals Inc. (XENE). Click either name above to swap in a different company.
Prothena Corporation plc is a late-stage clinical biotechnology firm focused on developing and commercializing innovative antibody therapies for neurodegenerative disorders, rare diseases and immune-related conditions. Its core pipeline targets unmet medical needs including amyloidosis, Parkinson's and Alzheimer's, serving key markets across North America, Europe and the Asia-Pacific.
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for neurological and rare disorders. Its core pipeline targets epilepsy, migraine and other central nervous system diseases, serving patients mainly across North America and Europe via partnerships to advance clinical candidates.
PRTA vs XENE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.0K | $0 |
| Net Profit | — | — |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | — | — |
| Revenue YoY | -99.0% | — |
| Net Profit YoY | 62.7% | -60.3% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.0K | $0 | ||
| Q3 25 | $2.4M | $0 | ||
| Q2 25 | $4.4M | $0 | ||
| Q1 25 | $2.8M | $7.5M | ||
| Q4 24 | $2.1M | $0 | ||
| Q3 24 | $970.0K | $0 | ||
| Q2 24 | $132.0M | $0 | ||
| Q1 24 | $50.0K | $0 |
| Q4 25 | — | — | ||
| Q3 25 | $-36.5M | $-90.9M | ||
| Q2 25 | $-125.8M | $-84.7M | ||
| Q1 25 | $-60.2M | $-65.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-59.0M | $-62.8M | ||
| Q2 24 | $66.9M | $-57.9M | ||
| Q1 24 | $-72.2M | $-47.9M |
| Q4 25 | — | — | ||
| Q3 25 | -1666.3% | — | ||
| Q2 25 | -1914.4% | — | ||
| Q1 25 | -2319.0% | -969.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -6857.0% | — | ||
| Q2 24 | 44.2% | — | ||
| Q1 24 | -163056.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | -1513.1% | — | ||
| Q2 25 | -2845.4% | — | ||
| Q1 25 | -2128.5% | -867.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | -6082.6% | — | ||
| Q2 24 | 50.7% | — | ||
| Q1 24 | -144478.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | $-0.68 | $-1.15 | ||
| Q2 25 | $-2.34 | $-1.07 | ||
| Q1 25 | $-1.12 | $-0.83 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.10 | $-0.81 | ||
| Q2 24 | $1.22 | $-0.75 | ||
| Q1 24 | $-1.34 | $-0.62 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $307.5M | $548.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $280.5M | $581.8M |
| Total Assets | $326.8M | $633.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $307.5M | $548.9M | ||
| Q3 25 | $330.8M | $462.3M | ||
| Q2 25 | $371.4M | $487.5M | ||
| Q1 25 | $417.9M | $549.6M | ||
| Q4 24 | $471.4M | $626.9M | ||
| Q3 24 | $519.3M | $654.0M | ||
| Q2 24 | $564.1M | $721.5M | ||
| Q1 24 | $546.5M | $699.6M |
| Q4 25 | $280.5M | $581.8M | ||
| Q3 25 | $295.0M | $559.5M | ||
| Q2 25 | $324.3M | $634.0M | ||
| Q1 25 | $437.7M | $704.0M | ||
| Q4 24 | $486.9M | $754.9M | ||
| Q3 24 | $534.4M | $797.8M | ||
| Q2 24 | $581.9M | $844.0M | ||
| Q1 24 | $502.4M | $887.7M |
| Q4 25 | $326.8M | $633.2M | ||
| Q3 25 | $352.6M | $607.8M | ||
| Q2 25 | $399.1M | $674.3M | ||
| Q1 25 | $495.3M | $743.3M | ||
| Q4 24 | $547.1M | $798.1M | ||
| Q3 24 | $595.3M | $835.9M | ||
| Q2 24 | $645.6M | $884.0M | ||
| Q1 24 | $623.2M | $919.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-163.6M | $-279.1M |
| Free Cash FlowOCF − Capex | — | $-279.9M |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-478.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-163.6M | $-279.1M | ||
| Q3 25 | $-40.6M | $-71.8M | ||
| Q2 25 | $-46.3M | $-64.2M | ||
| Q1 25 | $-53.4M | $-61.7M | ||
| Q4 24 | $-150.1M | $-181.4M | ||
| Q3 24 | $-45.2M | $-49.7M | ||
| Q2 24 | $16.0M | $-31.2M | ||
| Q1 24 | $-73.1M | $-46.2M |
| Q4 25 | — | $-279.9M | ||
| Q3 25 | — | $-72.0M | ||
| Q2 25 | — | $-64.4M | ||
| Q1 25 | — | $-61.7M | ||
| Q4 24 | — | $-184.5M | ||
| Q3 24 | — | $-50.3M | ||
| Q2 24 | — | $-32.7M | ||
| Q1 24 | — | $-46.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -822.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.24× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
